The American Gastroenterological Association has updated guidance for the treatment of ulcerative colitis to recommend using higher efficacy drugs in earlier stages of treatment, Medscape Medical News ...

Bethesda, MD (Nov. 15, 2024) — The American Gastroenterological Association (AGA) has released a new clinical guideline on the pharmacological management of moderate-to-severe ulcerative colitis, ...

How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...

A new drug, investigated by Amsterdam UMC together with colleagues around the world, is effective as a treatment against ulcerative colitis. With the clinical trial demonstrating a doubling in the ...

Older adults with acute severe ulcerative colitis have higher mortality, underscoring the need for targeted strategies to ...

Aminosalicylate (5-ASA) therapy is often the first treatment option for patients presenting with mild to moderate ulcerative colitis (UC). Symptom improvements can be observed within 2 to 4 weeks ...

An experimental monoclonal antibody treatment appears to ease the digestive disorder ulcerative colitis in patients who've failed other medications, a new trial shows. The treatment, tulisokibart, ...

Ulcerative Colitis Market grows at 5.4% CAGR (2025–2033), reaching US$ 12.79 Billion on rising biologic adoption, biosimilars, and personalized IBD therapies. North America leads the ulcerative ...